7 completed. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
Follow Refractory Primary Central Nervous System Neoplasm: new trials by email Literature Review of Refractory Primary Central Nervous System Neoplasm trials Research Report on Refractory Primary Central Nervous System Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma Irinotecan, Pevonedistat, Temozolomide - Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 30 | 2018-01-11 | 2024-10-22 |
| Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study - Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 33 | 2017-08-15 | 2025-01-14 |
| Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Laboratory Biomarker Analysis, Pharmacokinetic (PK) study, Prexasertib - Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 1 | Completed | Children's Oncology Group | 30 | 2017-02-27 | 2023-12-20 |
| Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Entinostat, Laboratory Biomarker Analysis, Pharmacological Study - Brain Stem Neoplasm, Pineal Region Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 21 | 2017-01-06 | 2023-10-17 |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas Pharmacological Study, Selinexor - Malignant Glioma, Recurrent Brain Neoplasm | Phase 1 | Completed | Children's Oncology Group | 59 | 2015-10-30 | 2025-01-14 |
| Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors Laboratory Biomarker Analysis, Pharmacological Study, Pomalidomide - Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2015-07-14 | 2022-04-25 |
| Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2012-11-14 | 2023-12-22 |
Central Nervous System Neoplasms (7) · Lymphoma (3) · Astrocytoma (1) · Brain Neoplasms (1) · Brain Stem Neoplasms (1) · Carcinoma, Medullary (1) · Glioma (1) · Melanoma (1) · Neurofibromatosis 1 (1) · Optic Nerve Glioma (1) · Pinealoma (1) · Thyroid Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Nervous System Diseases (7) · Nervous System Neoplasms (7) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms, Neuroepithelial (3)
Irinotecan (2) · Temozolomide (2) · cabozantinib (1) · entinostat (1) · pevonedistat (1) · pomalidomide (1) · prexasertib (1) · selinexor (1)
Children's Oncology Group (4) · National Cancer Institute (NCI) (3)
United States (7) · Canada (1)
Andrew Bukowinski (1) · Cynthia J Wetmore (1) · Jason R Fangusaro (1) · Jennifer H Foster (1) · Julia Glade-Bender (1) · Meredith K Chuk (1) · Stuart L Cramer (1)
PMID 33881209, PMID 39487711, PMID 39998852
UM1CA097452 (6), UM1CA081457 (1)